Cadrenal Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
CVKD$1.44+5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
FINANCIAL STATEMENTS
Contents
INDEX TO FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID #100) | F-2 |
|---|---|
| Balance Sheets at December 31, 2023 and 2022 | F-3 |
| Statements of Operations and Comprehensive Loss for the Year ended December 31, 2023, and for the period from January 25, 2022 (inception) through December 31, 2022 | F-4 |
| Statements of Changes in Stockholders’ Equity (Deficit) for the Year ended December 31, 2023, and for the period from January 25, 2022 (inception) through December 31, 2022 | F-5 |
| Statements of Cash Flows for the Year ended December 31, 2023, and for the period from January 25, 2022 (inception) through December 31, 2022 | F-6 |
| Notes to Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.